A new study suggests that a rechallenge with bevacizumab in combination with platinum-based chemotherapy may prolong progression-free survival (PFS) in patients with recurrent ovarian cancer (ROC) who already received this agent during first-line treatment. The study was presented by Italian … Read more
Results from analysis of clinical and tumor profiling data from ovarian cancer patients in the Clearity Foundation Data Repository were presented in two studies at the recent ASCO conference that took place June 1-5 in Chicago, Ill.
The first study
Pembrolizumab monotherapy is associated with antitumor activity in patients with advanced recurrent ovarian cancer, interim results from the phase 2suggest.
Notably, objective response rates among study subjects increased in tandem with increased programmed death-ligand 1 (PD-L1) expression, … Read more
Ovarian cancer can be tough to beat, particularly if it returns after initial treatment, but new research offers a glimmer of hope.
One study found that a new targeted “immunotherapy” to treat ovarian cancer that has come back looked promising … Read more
The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the … Read more
Whenever Joan Janssen meets fellow ovarian cancer patients, she shares words of wisdom that she’s gained from seven years of living with the disease. “This is a recurring disease; don’t be stunned if it comes back,” she tells them. “You … Read more
For many people diagnosed with cancer, the symptoms are obvious. Bumps, lumps and blood where it shouldn’t be are all clear-cut warning signs that something could be wrong.
But for Narell Whitehead, a chance encounter with a TV ad was … Read more
The US Food and Drug Administration (FDA) has granted priority review status to rucaparib as maintenance therapy for women with recurrent ovarian cancer, according to the drug’s developer. The application is for women who are platinum sensitive, and in complete … Read more
By: Susan Gubar
Toward the end of another unexpected year of existence, outliving a poor prognosis of late-stage cancer rouses me in the dark. Such an awakening is quite different from the fretful insomnia that accompanied the dire diagnosis. Especially … Read more
One of the biggest challenges for cancer survivors can be simply not thinking about their cancer once they’ve tamed the beast and been declared cancer-free. As an ovarian cancer patient, I’d venture to speculate that it’s even harder for those … Read more
Avastin (bevacizumab) gained an expanded FDA approval to treat patients with platinum-sensitive recurrent ovarian cancer as a part of a combination regimen with chemotherapy followed by continued use of the angiogenesis inhibitor, according to the drug developer, Genentech.
The approval … Read more